Is LNAI Worth Buying in 2026?

Lunai Bioworks Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-05-03

Here’s whether Lunai Bioworks Inc. Common Stock (LNAI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: RSI 37 — healthy momentum range. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-18.86% over 10 days); 3-month momentum negative (-57.8%). Currently 80.7% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

LNAI is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 37.4 sits in the neutral zone — momentum is neither stretched nor exhausted. With ~7 months of trading history, the return since first available bar is -75.0%. The current 80.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 7 months ago → $2,499 today

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 100-day MA ($0.63)
Above 25-day MA ($0.35)
RSI(10) neutral zone (30–70) — currently 35.8
Positive return (-66.0%)
!Within 10% of period high (−80.7%)
Period Range $0.32
$0.15 $1.66
RSI (10) 35.8
0 · OversoldOverbought · 100

Key Metrics

Price$0.32
Period Return-66.0%
Period High$1.66
Period Low$0.15
Drawdown−80.7%
MA-25$0.35
MA-100$0.63
RSI (10)35.8
Avg Volume (30d)20.1M
vs. SPYtrailed by 72.0%

Trade LNAI

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers